A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
Phase 3
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-jRCT2080222355
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Male or female patients at least 18 years of age who have been diagnosed with RA and have completed the final study visit in a previous baricitinib RA study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of baricitinib in rheumatoid arthritis pathogenesis?
How does baricitinib compare to TNF inhibitors in long-term RA management outcomes?
Which biomarkers correlate with baricitinib response in Japanese RA patients?
What adverse events are associated with JAK inhibitors like baricitinib in RA trials?
Are there combination therapies involving baricitinib and DMARDs for refractory rheumatoid arthritis?